
News


Mahmoud Khaimi, MD, briefly discussed the launch of the iTrack Advance handheld device at the 2023 ASCRS annual meeting in San Diego.

Lisa Nijm, MD, discussed Preservative Freedom, a coalition that has been put together by Thea to help bring attention and bring awareness to creating preservative-free drops for all patients at the 2023 ASCRS annual meeting in San Diego.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

A modified illuminated endolaser could be an efficient substitute for cryotherapy or indirect laser retinopexy during primary scleral buckling.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

Sam Garg, MD, discussed his paper on the 36-month outcomes for the Juvene modular intraocular lens at the 2023 ASCRS annual meeting in San Diego.

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

A team of researchers has now developed an approach to gather and compile a great deal of information about organoids and their development. The team applied its approach to the organoids of the human retina, which they derived from stem cells.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

Inherited Retinal Diseases (IRD are genetic disorders that can cause severe vision loss or even blindness.

Daniel Chang, MD, discussed his paper on a study comparing TECNIS Symfony OptiBlue IOL with the TECNIS Symfony Legacy IOL at the 2023 ASCRS annual meeting in San Diego.

According to researchers, these chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

Robert Lin, MD, founder of IQ Laser Vision, discussed the new CellChek 20 at the 2023 ASCRS annual meeting in San Diego.

Rob Thornhill, CEO of Centricity Vision, discussed the FDA clearing of ZeptoLink at the 2023 ASCRS annual meeting in San Diego.

According to the organization, the trip marks the 12th training project in Vietnam for the Flying Eye Hospital, including one virtual project on Cybersight, Orbis's telemedicine platform.

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Patrick Herde, General Manager of Ophthalmology and Optometry at ModMed, discussed a retrospective on the company's 10-year anniversary 2023 ASCRS annual meeting in San Diego.

Denise M. Visco, MD, discussed her presentation on astigmatism management with a dual-pulse femtosecond laser called ALLY, from Lensar, at the 2023 ASCRS annual meeting in San Diego.

Edward Hu, MD, PhD, discussed his paper on the single surgeon retrospective comparative analysis of 517 eyes of two subgroups of routine cataract surgery at the 2023 ASCRS annual meeting in San Diego.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

At the American Society of Cataract and Refractive Surgery annual meeting in San Diego, data was presented from the STORM study that demonstrate vision quality to be a major driver of the patient decision to undergo surgery.

According to the company, the announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis.

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.

According to the company, a PDUFA date has been set for December 22, 2023.

Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth

Bharti Nihalani-Gangwani, MD, from the Department of Ophthalmology, Children’s Hospital, and Deborah VanderVeen, MD, from the Department of Ophthalmology, Harvard Medical School, Boston, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting.

Rob Weinstock, MD from the Eye Institute of West Florida presented on his experience working with the ALLY cataract femtosecond laser cataract system from LENSAR at the 2023 ASCRS annual meeting in San Diego.



.png)


